Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Influenza viral particles harboring the SARS-CoV-2 spike RBD as a combination respiratory disease vaccine

View ORCID ProfileRyan R. Chaparian, View ORCID ProfileAlfred T. Harding, View ORCID ProfileKristina Riebe, View ORCID ProfileAmelia Karlsson, View ORCID ProfileGregory D. Sempowski, View ORCID ProfileNicholas S. Heaton, View ORCID ProfileBrook E. Heaton
doi: https://doi.org/10.1101/2021.04.30.441968
Ryan R. Chaparian
1Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ryan R. Chaparian
Alfred T. Harding
1Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alfred T. Harding
Kristina Riebe
2Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kristina Riebe
Amelia Karlsson
2Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amelia Karlsson
Gregory D. Sempowski
2Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gregory D. Sempowski
Nicholas S. Heaton
1Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America
2Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicholas S. Heaton
  • For correspondence: brook.heaton@duke.edu nicholas.heaton@duke.edu
Brook E. Heaton
1Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brook E. Heaton
  • For correspondence: brook.heaton@duke.edu nicholas.heaton@duke.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Vaccines targeting SARS-CoV-2 have gained emergency FDA approval, however the breadth against emerging variants and the longevity of protection remains unknown. Post-immunization boosting may be required, perhaps on an annual basis if the virus becomes an endemic pathogen. Seasonal influenza virus vaccines are already developed every year, an undertaking made possible by a robust global vaccine production and distribution infrastructure. To create a seasonal combination vaccine targeting influenza viruses and SARS-CoV-2 that is also amenable to frequent reformulation, we have developed a recombinant influenza A virus (IAV) genetic platform that “reprograms” the virus to package an immunogenic domain of the SARS-CoV-2 spike (S) protein onto IAV particles. Vaccination with this combination vaccine elicits neutralizing antibodies and provides protection from lethal challenge with both pathogens. This technology may allow for leveraging of established influenza vaccine infrastructure to generate a cost-effective and scalable seasonal vaccine solution for both influenza and coronaviruses.

Competing Interest Statement

Duke University has filed for intellectual property protection of the viral genetic manipulation approaches in this manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 30, 2021.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Influenza viral particles harboring the SARS-CoV-2 spike RBD as a combination respiratory disease vaccine
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Influenza viral particles harboring the SARS-CoV-2 spike RBD as a combination respiratory disease vaccine
Ryan R. Chaparian, Alfred T. Harding, Kristina Riebe, Amelia Karlsson, Gregory D. Sempowski, Nicholas S. Heaton, Brook E. Heaton
bioRxiv 2021.04.30.441968; doi: https://doi.org/10.1101/2021.04.30.441968
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Influenza viral particles harboring the SARS-CoV-2 spike RBD as a combination respiratory disease vaccine
Ryan R. Chaparian, Alfred T. Harding, Kristina Riebe, Amelia Karlsson, Gregory D. Sempowski, Nicholas S. Heaton, Brook E. Heaton
bioRxiv 2021.04.30.441968; doi: https://doi.org/10.1101/2021.04.30.441968

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Microbiology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4382)
  • Biochemistry (9594)
  • Bioengineering (7091)
  • Bioinformatics (24861)
  • Biophysics (12615)
  • Cancer Biology (9956)
  • Cell Biology (14354)
  • Clinical Trials (138)
  • Developmental Biology (7948)
  • Ecology (12105)
  • Epidemiology (2067)
  • Evolutionary Biology (15988)
  • Genetics (10925)
  • Genomics (14739)
  • Immunology (9869)
  • Microbiology (23670)
  • Molecular Biology (9484)
  • Neuroscience (50866)
  • Paleontology (369)
  • Pathology (1539)
  • Pharmacology and Toxicology (2683)
  • Physiology (4014)
  • Plant Biology (8657)
  • Scientific Communication and Education (1508)
  • Synthetic Biology (2394)
  • Systems Biology (6435)
  • Zoology (1346)